Management of GLP-1 Receptor Agonists for Colonoscopy

Introduction to GLP-1 Receptor Agonist Management

The U.S. Multi-Society Task Force guidelines acknowledge that GLP-1 RAs delay gastric emptying but do not specifically recommend discontinuation for bowel preparation purposes, as the evidence shows no significant difference in inadequate bowel preparation rates between GLP-1 RA users and controls 1

For colonoscopy with sedation, GLP-1 RAs must be stopped due to the aspiration risk from delayed gastric emptying, with recommended holding periods before the procedure: 3 weeks for semaglutide, tirzepatide, and dulaglutide, and 3-4 days for liraglutide 2
Discontinuation for only 7 days is insufficient, as studies show retained gastric contents persist even after 10-14 days of discontinuation, and the American Society of Anesthesiologists initially recommended 1 week for weekly agents, but emerging evidence demonstrates this is inadequate 2

For colonoscopy without sedation, GLP-1 RA can be continued without interruption, using standard bowel preparation protocols, with no special precautions needed beyond standard preparation 1
For colonoscopy with sedation, determine the medication and calculate the holding period, assess patient indication, and consider postponing elective colonoscopy if the adequate holding period is not achieved, with the American Gastroenterological Association recommending full stomach precautions, including point-of-care gastric ultrasound, prokinetic drugs, and rapid sequence intubation with full airway protection 2

The mechanism of GLP-1 RAs delaying gastric emptying is clear, through inhibition of gastric peristalsis, increased pyloric tone, and vagal nerve pathway activation, with documented clinical consequences, including 24.2% of semaglutide users having residual gastric content vs 5.1% of controls, even after 12+ hour fasting, and multiple case reports documenting pulmonary aspiration requiring ICU admission 2

For patients with diabetes, the benefits of glycemic control may outweigh delayed gastric emptying issues, requiring individualized risk-benefit assessment with endocrinology consultation, with the American Diabetes Association recommending adequate discontinuation with bridging therapy if needed 2
Documentation requirements before the procedure include indication and dose of GLP-1 RA, date commenced and last dose taken, symptoms of nausea, vomiting, or abdominal distention, and concomitant medications affecting gastric emptying, as recommended by the American Society of Gastrointestinal Endoscopy 2